Table 1. Clinical characteristics according to A20 expression.
| A20-low, n = 390 (%) | A20-high, n = 52 (%) | P value | |
|---|---|---|---|
| Age | 0.011 | ||
| >35 | 355(91.0) | 41(78.8) | |
| ≤35 | 35(9.0) | 11(21.2) | |
| T stage | 0.006 | ||
| 1 | 141(36.2) | 13(25.0) | |
| 2 | 230(59.0) | 30(57.7) | |
| 3 | 18(4.6) | 8(15.4) | |
| 4 | 1(0.3) | 1(1.9) | |
| N stage | 0.045 | ||
| 0 | 219(56.2) | 19(37.3) | |
| 1 | 111(28.5) | 19(37.3) | |
| 2 | 33(8.5) | 6(11.8) | |
| 3 | 27(6.9) | 8(15.4) | |
| AJCC stage* | 0.030 | ||
| I | 133(34.1) | 12(23.1) | |
| II | 188(48.2) | 24(43.2) | |
| III | 67(17.2) | 14(26.9) | |
| IV | 2(0.5) | 2(3.8) | |
| HG1 | 0.299 | ||
| I, II | 204(52.3) | 33(63.5) | |
| III | 164(42.1) | 19(36.5) | |
| ER1 | 0.765 | ||
| Positive | 172(44.1) | 21(40.4) | |
| Negative | 216(55.4) | 30(57.7) | |
| PR1 | 0.412 | ||
| Positive | 172(44.1) | 24(46.2) | |
| Negative | 216(55.4) | 27(51.9) | |
| HER-21 | 0.837 | ||
| Positive | 65(16.7) | 9(17.3) | |
| Negative | 248(63.6) | 31(59.6) | |
| Subtype1 | 0.503 | ||
| Luminal/HER2(-) | 108(27.7) | 17(32.7) | |
| HER2(+) | 117(30) | 15(28.8) | |
| TNBC | 140(35.9) | 14(26.9) | |
| Operation method | 0.760 | ||
| Total mastectomy | 253(64.9) | 35(67.3) | |
| Breast conserving | 137(35.1) | 17(32.7) | |
| LVI1 | 0.079 | ||
| Positive | 44(11.3) | 11(21.2) | |
| Negative | 315(80.8) | 40(76.9) | |
| Chemotherapy | 0.724 | ||
| Done | 303(77.7) | 39(75.0) | |
| Not done/unknown | 87(22.3) | 13(25.0) | |
| Radiotherapy | 0.763 | ||
| Done | 154(39.5) | 19(36.5) | |
| Not done/unknown | 236(60.5) | 33(63.5) | |
| Endocrine therapy | 0.288 | ||
| Done | 153(39.2) | 16(30.8) | |
| Not done/unknown | 237(60.8) | 36(69.2) | |
| Trastuzumab | 0.235 | ||
| Done | 15(3.8) | 0 | |
| Not done/unknown | 375(96.2) | 52(100) |
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; HG, histologic grade; TNBC, triple negative breast cancer; LVI, Lymphovascular invasion
*AJCC stage was performed based on 7th edition
1Missing value
2HER-2 positive was defined by 3 positive on immunohistochemistry or amplification on fluorescence in situ hybridization